Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
Cross-Border Impact Ventures (CBIV) is a women-owned, women-led impact venture capital firm based in Toronto, Canada. Founded in 2021, the firm focuses on investing in health technology companies that aim to improve health outcomes for women, children, and adolescents globally. The firm has quickly established itself in the venture capital landscape, winning the Best HealthTech Investment Company award in 2024 in Canada.
CBIV manages the Women’s and Children’s Health Technology Fund, which has raised over $90 million in commitments. This fund emphasizes investments in medical devices, diagnostics, therapeutics, and digital health innovations. The firm operates primarily in North America and Europe, while also seeking opportunities in low- and middle-income countries. The firm’s approach combines a strong commitment to social impact with the pursuit of financial returns.
Cross-Border Impact Ventures invests in early-growth stage health technology companies, specifically targeting sectors such as medical devices, diagnostics, therapeutics, and digital health innovations. The firm prioritizes companies that address significant market opportunities in women's, children's, and adolescent health, with a particular emphasis on gender health inequalities. Their investment strategy includes a gender and diversity lens, aiming for both positive social impact and financial returns.
Investment stages include Seed, Series A, and Series B, with check sizes typically aligned with the needs of early-growth companies. CBIV's geographic focus spans North America, Europe, and Latin America, while also seeking scalable opportunities in low- and middle-income countries. The firm emphasizes cross-border commercialization and scalability, particularly in emerging markets, enhancing the growth potential of its investments.
Cross-Border Impact Ventures has a notable portfolio of 8 companies that reflect its commitment to addressing gender health inequalities. Key portfolio companies include:
These companies exemplify CBIV's focus on health technology solutions that improve health outcomes for underserved populations.
Annie Thériault: Managing Partner with a background in health technology investments and a focus on gender health initiatives.
Donna Parr: Managing Partner who brings extensive experience in venture capital and impact investing.
Hamza Kayani: Investment Analyst specializing in early-stage health technology companies.
Hannah Sharpe: ESG and Health Impact Associate with expertise in measuring social impact metrics.
Juanita Cortés: Chief Financial Officer responsible for financial strategy and operations.
Megan Dover: Junior Partner with a focus on portfolio management and growth strategies.
Pooja Sikka: Venture Partner with experience in scaling health tech startups.
Tasha Noronha: Partnerships & Operations Manager facilitating collaborations and operational efficiencies.
To pitch to Cross-Border Impact Ventures, founders should use the preferred channel available on their website at crossborder.ventures. The pitch deck should include a clear overview of the business model, market analysis, and specific details on how the product addresses gender health inequalities. Response times may vary, but founders can expect feedback within a few weeks.
In January 2024, Cross-Border Impact Ventures announced the final close of its Women’s and Children’s Health Technology Fund, exceeding $90 million in commitments. This milestone reflects strong validation from tier-1 limited partners, including the Bill & Melinda Gates' Global Health Investment Corporation and Johnson & Johnson Impact Ventures.
The firm has been actively engaging in the health technology space, partnering with Grand Challenges Canada to enhance its impact. Recent portfolio highlights include the successful launch of innovative solutions in maternal and child health and chronic disease management.
What are Cross-Border Impact Ventures' investment criteria?
CBIV invests in early-growth stage health technology companies that focus on women's, children's, and adolescent health. The firm seeks companies that address significant market opportunities and demonstrate potential for both social impact and financial returns.
How can I apply or pitch to Cross-Border Impact Ventures?
Founders can pitch their ideas through the firm's website at crossborder.ventures. It is recommended to include a clear business model, market analysis, and details on how the product addresses gender health inequalities.
What makes Cross-Border Impact Ventures different from other VC firms?
CBIV is distinguished by its women-owned and women-led structure, focusing exclusively on health technology that serves women, children, and adolescents. The firm emphasizes investments that yield both social impact and financial returns.
What is the geographic scope of Cross-Border Impact Ventures?
The firm primarily invests in North America and Europe, while also exploring opportunities in low- and middle-income countries. This cross-border approach enhances the scalability of their investments.
What is the typical fund size and check size for investments?
CBIV's Women’s and Children’s Health Technology Fund has raised over $90 million, with check sizes varying based on the stage of the company and its specific needs.
What kind of post-investment involvement does Cross-Border Impact Ventures have?
CBIV provides strategic support to its portfolio companies, leveraging its expertise in health technology and impact metrics to drive both social and financial returns. The firm emphasizes cross-border commercialization and scalability.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.